Home › Merck to Present New Data on ZEPATIER (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting 2016
 

Keywords :   


Merck to Present New Data on ZEPATIER (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting 2016

2016-10-03 14:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the companys chronic hepatitis C virus (HCV) clinical development programs will be presented at The Liver Meeting 2016. Fifteen scientific abstracts, including seven oral and eight poster presentations, will highlight findings from Mercks HCV clinical development programs. Language: English Contact: MerckMedia:Doris Li, 908-740-1903Ian McConnell, 908-740-1921orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the data development present

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
24.04US Senate passes bill that could see TikTok banned
24.04Pensioners' fears over income tax burden
24.04The women-only co-working spaces fighting to survive
24.04Spotify turns up volume to make record profits
23.04Tesla profits nosedive as more job cuts announced
23.04Global Halal Cosmetics Market To Grow by Over $50 Billion in 2030: Research and Markets
23.04iBeauty Brands Acquires Voloom
23.04Wausau Coated Products promotes Gina Roemke
More »